Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: IgE synthesis inhibitors - Pfizer

Drug Profile

Research programme: IgE synthesis inhibitors - Pfizer

Alternative Names: Research programme: IgE secretion inhibitors - Pfizer; Research programme: interleukin-4 pathway inhibitors - Pfizer

Latest Information Update: 13 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic asthma; Hypersensitivity

Most Recent Events

  • 06 Sep 2004 Data presented at the 18th International Symposium of Medicinal Chemistry (ISMC-2004) have been added to the adverse events and Obstructive Airways Disease pharmacodynamics sections
  • 07 Oct 2003 The drug targets accepted by Pfizer have entered the compound screening phase at Pfizer
  • 26 Jun 2002 Rigel Pharmaceuticals has concluded its research collaboration with Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top